ProQR Therapeutics (NASDAQ:PRQR) Receives $9.50 Average PT from Brokerages

ProQR Therapeutics (NASDAQ:PRQR) has been assigned an average rating of “Buy” from the six analysts that are currently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $9.50.

Several equities analysts have recently weighed in on the stock. HC Wainwright raised their price objective on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, March 14th. Citigroup upgraded shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price target for the company in a research report on Monday, March 10th. JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 target price on shares of ProQR Therapeutics in a research report on Thursday, December 12th. StockNews.com downgraded ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. Finally, Chardan Capital reissued a “buy” rating and set a $4.00 target price on shares of ProQR Therapeutics in a research note on Friday, March 14th.

ProQR Therapeutics Trading Down 5.6 %

Shares of NASDAQ:PRQR opened at $1.52 on Friday. ProQR Therapeutics has a twelve month low of $1.50 and a twelve month high of $4.62. The firm has a market cap of $159.92 million, a P/E ratio of -4.75 and a beta of 0.24. The company has a 50 day moving average of $2.11 and a 200-day moving average of $2.60.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. OneDigital Investment Advisors LLC raised its stake in shares of ProQR Therapeutics by 37.0% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 15,550 shares in the last quarter. BNP Paribas Financial Markets increased its stake in ProQR Therapeutics by 14.2% during the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 7,300 shares during the period. Ballentine Partners LLC acquired a new stake in shares of ProQR Therapeutics during the 4th quarter worth approximately $61,000. M&T Bank Corp bought a new stake in shares of ProQR Therapeutics during the fourth quarter valued at approximately $330,000. Finally, Raymond James Financial Inc. acquired a new position in shares of ProQR Therapeutics in the fourth quarter valued at $260,000. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).